February 2024
1. ROSAS-SALAZAR C, Gebretsadik T, Dupont WD, Hartert TV, et al
   The INSPIRE study: RSV infection during infancy - Authors' reply.
   Lancet. 2024;403:729-730.
   

   >> Share

   
   January 2024
2. QUINT JK, Shah PL
   What trials do and do not tell us about treatments for severe asthma.
   Lancet. 2024;403:224-226.
   

   >> Share

   
   
3. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
   Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
   Lancet. 2024;403:147-159.
   

   >> Share

   
   
4. MOUSSA S, Netchiporouk E
   Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
   Lancet. 2024;403:118-119.
   

   >> Share

   
   December 2023
5. DRUCKER NA, Cox CS Jr
   Adult presentation of congenital tracheooesophageal fistula treated as asthma and recurrent respiratory infections.
   Lancet. 2023;402:2326-2327.
   

   >> Share

   
   
6. JACKSON DJ, Heaney LG, Humbert M, Kent BD, et al
   Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
   Lancet. 2023 Dec 7:S0140-6736(23)02284-5. doi: 10.1016/S0140-6736(23)02284.
   

   >> Share

   
   November 2023
7. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
   Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
   Lancet. 2023;402:1834.
   

   >> Share

   
   
8. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
   Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
   Lancet. 2023;402:1833-1834.
   

   >> Share

   
   
9. GEDEON E, Henderson M, Leyland AH, Allik M, et al
   Association between care experience and mental health hospitalisation among children in Scotland, with a focus on chronic conditions (CHiCS): a population-wide longitudinal study using administrative data.
   Lancet. 2023;402 Suppl 1:S5.
   

   >> Share

   
   
10. ALYAMI RA, Simpson R, Oliver P, Julious SA, et al
    Evaluation of the impact of letters to GP practices to promote asthma prescription uptake in school-age children during summer (TRAINS study): a pragmatic cluster-randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S22.
    

    >> Share

    
    September 2023
11. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    

    >> Share

    
    July 2023
12. LEVY ML, Bateman ED, Allan K, Bacharier LB, et al
    Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective.
    Lancet. 2023 Jul 19:S0140-6736(23)01358-2. doi: 10.1016/S0140-6736(23)01358.
    

    >> Share

    
    June 2023
13. PETRUSHKIN H, Solebo AL
    Imaging inflammation in early-onset sarcoidosis: granulomatous anterior uveitis in a 7-year-old girl.
    Lancet. 2023;401:1963.
    

    >> Share

    
    April 2023
14. BILLARD MN, Bont LJ
    The link between respiratory syncytial virus infection during infancy and asthma during childhood.
    Lancet. 2023 Apr 19:S0140-6736(23)00672-4. doi: 10.1016/S0140-6736(23)00672.
    

    >> Share

    
    
15. ROSAS-SALAZAR C, Chirkova T, Gebretsadik T, Chappell JD, et al
    Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): a population-based, prospective birth cohort study.
    Lancet. 2023 Apr 19:S0140-6736(23)00811-5. doi: 10.1016/S0140-6736(23)00811.
    

    >> Share

    
    
16. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    

    >> Share

    
    
17. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    

    >> Share

    
    February 2023
18. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    

    >> Share

    
    
19. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    

    >> Share

    
    January 2023
20. PORSBJERG C, Melen E, Lehtimaki L, Shaw D, et al
    Asthma.
    Lancet. 2023 Jan 19:S0140-6736(22)02125-0. doi: 10.1016/S0140-6736(22)02125.
    

    >> Share

    
    December 2022
21. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    

    >> Share

    
    
22. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    

    >> Share

    
    September 2022
23. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    

    >> Share

    
    
24. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    

    >> Share

    
    August 2022
25. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    

    >> Share

    
    
26. JACKSON DJ, Bacharier LB, Gergen PJ, Gagalis L, et al
    Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial.
    Lancet. 2022;400:502-511.
    

    >> Share

    
    
27. KELLY RS, Weiss ST
    Biologic therapies for asthma in underserved populations.
    Lancet. 2022;400:471-473.
    

    >> Share

    
    July 2022
28. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    

    >> Share

    
    
29. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    

    >> Share

    
    June 2022
30. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    

    >> Share

    
    
31. PERKIN MR
    Early introduction of allergenic food for all infants.
    Lancet. 2022;399:2329-2331.
    

    >> Share

    
    May 2022
32. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    

    >> Share

    
    April 2022
33. LOMMATZSCH M, Brusselle GG, Canonica GW, Jackson DJ, et al
    Disease-modifying anti-asthmatic drugs.
    Lancet. 2022;399:1664-1668.
    

    >> Share

    
    March 2022
34. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    

    >> Share

    
    
35. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    

    >> Share

    
    January 2022
36. JONES SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, et al
    Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study.
    Lancet. 2022;399:359-371.
    

    >> Share

    
    
37. GREENHAWT M, Shaker M, Abrams EM
    Peanut oral immunotherapy in very young children.
    Lancet. 2022;399:336-337.
    

    >> Share

    
    October 2021
38. ASHER MI, Rutter CE, Bissell K, Chiang CY, et al
    Worldwide trends in the burden of asthma symptoms in school-aged children: Global Asthma Network Phase I cross-sectional study.
    Lancet. 2021;398:1569-1580.
    

    >> Share

    
    
39. PIJNENBURG MW, Nantanda R
    Rising and falling prevalence of asthma symptoms.
    Lancet. 2021;398:1542-1543.
    

    >> Share

    
    
40. JANKAUSKAITE L, Oostenbrink R
    Childhood lower respiratory tract infections: more evidence to do less.
    Lancet. 2021;398:1383-1384.
    

    >> Share

    
    
41. BUSH A, Pavord ID
    Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes.
    Lancet. 2021 Oct 14. pii: S0140-6736(21)02244.
    

    >> Share

    
    August 2021
42. SOAR J, Becker LB, Berg KM, Einav S, et al
    Cardiopulmonary resuscitation in special circumstances.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01257.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share